Coherus Oncology (CHRS) Equity Average (2016 - 2025)
Coherus Oncology (CHRS) has disclosed Equity Average for 12 consecutive years, with $74.4 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 167.64% to $74.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $74.4 million through Dec 2025, up 167.64% year-over-year, with the annual reading at -$35.5 million for FY2025, 78.19% up from the prior year.
- Equity Average hit $74.4 million in Q4 2025 for Coherus Oncology, down from $103.8 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $204.3 million in Q1 2021 to a low of -$185.6 million in Q2 2023.
- Historically, Equity Average has averaged -$31.1 million across 5 years, with a median of -$71.4 million in 2022.
- Biggest five-year swings in Equity Average: plummeted 3588.37% in 2023 and later soared 220.64% in 2025.
- Year by year, Equity Average stood at $114.2 million in 2021, then crashed by 202.65% to -$117.3 million in 2022, then tumbled by 39.43% to -$163.5 million in 2023, then soared by 32.74% to -$110.0 million in 2024, then skyrocketed by 167.64% to $74.4 million in 2025.
- Business Quant data shows Equity Average for CHRS at $74.4 million in Q4 2025, $103.8 million in Q3 2025, and -$31.8 million in Q2 2025.